Federal Court of Appeal finds that Apotex did not fail to mitigate its damages in relation to Apo-Trazadone drug submission

Published date30 May 2017
Law FirmSmart & Biggar
AuthorAbigail Smith
Subject MatterSettlement,Appeals,Standard of Care,Loss Mitigation,Negligence,Drug Approvals,Calculation of Damages,Pharmaceutical Patents,Canada,Apotex,Cross-Appeals,Health Canada,Malfeasance

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT